<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00856310</url>
  </required_header>
  <id_info>
    <org_study_id>R475-PN-0817</org_study_id>
    <nct_id>NCT00856310</nct_id>
  </id_info>
  <brief_title>A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study of the Safety and Tolerability of REGN475 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled single-dose study of the safety and
      tolerability of intravenously administered REGN475 in healthy volunteers. The primary
      objective of the study is to assess the safety and tolerability of REGN475. The secondary
      objectives are to characterize the pharmacokinetic and immunogenicity profiles of REGN475.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events in subjects treated with REGN475 or placebo.</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of REGN475.</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The presence or absence of antibodies against REGN475.</measure>
    <time_frame>16 Week follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose 1 REGN475</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose 2 of REGN475</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose 2 of REGN475</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose 1 of REGN475</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose 2 of REGN475</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose 1 REGN475 subcutaneous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose 2 REGN475 subcutaneous administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>REGN475 (SAR164877)</intervention_name>
    <description>Subcutaneous administration REGN475 (SAR164877)</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or female volunteers, in general good health and 21 to 65 years of age.

          -  Female volunteers must be post-menopausal for at least 1 year or surgically sterile.

        Key Exclusion Criteria:

          -  Significant concomitant illness such as, but not limited to, cardiac, renal,
             neurological, endocrinological, GI, hepatic, metabolic or lymphatic disease that would
             adversely affect the subject's participation in this study or interpretation of
             safety/ PK data

          -  Participation in any clinical research study evaluating another investigational drug
             or therapy within 3 weeks or at least 5 half-lives of the investigational drug,
             whichever is longer, prior to the Screening Visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2009</study_first_submitted>
  <study_first_submitted_qc>March 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2009</study_first_posted>
  <last_update_submitted>May 9, 2012</last_update_submitted>
  <last_update_submitted_qc>May 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

